On Tuesday, Esperion Therapeutics Inc. (NASDAQ: ESPR) opened higher 3.40% from the last session, before settling in for the closing price of $2.06. Price fluctuations for ESPR have ranged from $0.71 to $3.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 7.64% over the past five years. Company’s average yearly earnings per share was noted 86.70% at the time writing. With a float of $194.16 million, this company’s outstanding shares have now reached $196.22 million.
Let’s look at the performance matrix of the company that is accounted for 240 employees. In terms of profitability, gross margin is 81.81%, operating margin of 1.78%, and the pretax margin is -35.46%.
Esperion Therapeutics Inc. (ESPR) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Esperion Therapeutics Inc. is 1.05%, while institutional ownership is 70.67%. The most recent insider transaction that took place on Oct 17 ’24, was worth 227. In this transaction Chief Commercial Officer of this company sold 107 shares at a rate of $2.12, taking the stock ownership to the 162,552 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Officer proposed sale 107 for $2.12, making the entire transaction worth $227.
Esperion Therapeutics Inc. (ESPR) Latest Financial update
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.37 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.43) by 0.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 23.09% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Check out the current performance indicators for Esperion Therapeutics Inc. (ESPR). In the past quarter, the stock posted a quick ratio of 1.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.88, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach 0.16 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (NASDAQ: ESPR) saw its 5-day average volume 3.02 million, a negative change from its year-to-date volume of 6.28 million. As of the previous 9 days, the stock’s Stochastic %D was 65.81%. Additionally, its Average True Range was 0.13.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 35.71%, which indicates a significant decrease from 81.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.09% in the past 14 days, which was higher than the 72.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.84, while its 200-day Moving Average is $2.24. Nevertheless, the first resistance level for the watch stands at $2.17 in the near term. At $2.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.30. If the price goes on to break the first support level at $2.04, it is likely to go to the next support level at $1.96. The third support level lies at $1.91 if the price breaches the second support level.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
There are currently 189,460K shares outstanding in the company with a market cap of 417.95 million. Presently, the company’s annual sales total 116,330 K according to its annual income of -209,250 K. Last quarter, the company’s sales amounted to 73,830 K and its income totaled -61,930 K.
